[Chronic myeloid leukemia in health regions 1, 3, 4 and 5 during the period 1990-96]
Insights
This study tracked 141 chronic myeloid leukemia patients in Norway over six years. Survival rates were significantly lower for older patients and those not receiving stem cell transplants.
Area of Science:
- Hematology
- Oncology
- Epidemiology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Understanding treatment patterns and outcomes is crucial for improving patient care.
- Regional variations in CML incidence and management warrant investigation.
Purpose of the Study:
- To investigate the treatment, clinical course, and outcomes of CML patients over a six-year period in a specific Norwegian region.
- To determine the incidence rate of CML in the studied population.
- To analyze survival rates based on age and treatment modality.
Main Methods:
- Retrospective analysis of 141 CML patients diagnosed within a defined geographical area over six years.
- Data collection on patient demographics, primary treatments (hydroxyurea, interferon), and allogeneic stem cell transplantation (aSCT).
- Calculation of incidence rates, median survival, and five-year survival rates stratified by age and treatment.
Main Results:
- The incidence of CML was 0.9 per 100,000 person-years, with a median patient age of 62.
- Hydroxyurea was the primary treatment for over 70% of patients.
- Median survival for all patients was 36 months; five-year survival was 33%. Patients <55 years had a 56% five-year survival, while those >55 had 16%.
Conclusions:
- Younger CML patients (<55 years) who underwent aSCT had a 72% five-year survival rate, significantly higher than older patients.
- Treatment with hydroxyurea and interferon was common, but outcomes varied significantly by age and transplant status.
- Leukemia remained the primary cause of death, though transplantation-related mortality was observed in younger, transplanted patients.
Abstract:
The aim of the present investigation was to obtain information about treatment, clinical course and outcome for all patients with chronic myeloid leukaemia through a six-year period in a defined part of Norway. A total number of 141 patients fulfilled the diagnostic criteria. This is equivalent to 0.9 patients per 100,000 per year. The median age was 62 years. More than 70% of the patients were primarily treated with hydroxyurea, either alone or combined with interferon. 40 out of 57 patients younger than 55 years underwent allogeneic stem cell transplantation. Median survival for all patients was 36 months with an estimated five-year survival rate of 33%. Patients older than 55 years had a median survival of 30 months with 16% alive after five years. The five-year survival rate for patients younger than 55 years was 56%, for transplanted patients 72%. 60 of 84 patients older than 55 years have died after 4 1/2 years median observation time. Two thirds of those died of leukaemia; one third of other causes. 23 of 57 patients younger than 55 years have died. 11 of them had had transplantations and most of them died from transplantation-related causes, while leukaemia was the dominating cause of death in the others.
More Related Videos
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...